#39 - Ted Schaeffer, M.D., Ph.D.: How to catch, treat, and survive prostate cancer

Feb 4, 2019 Episode Page ↗
Overview

Dr. Ted Schaeffer, Professor and Chair of Urology at Northwestern, discusses prostate cancer screening (PSA, 4K, MRI), treatment, and controversies. He shares insights on surgical advancements, research, and advice for MD-PhD students, offering a comprehensive overview for men and their families.

At a Glance
16 Insights
2h 31m Duration
15 Topics
8 Concepts

Deep Dive Analysis

Ted Schaeffer's Unique Path to an MD-PhD

Scientific Transition: Single Gene Focus to Complex Systems

Advice for MD-PhD Students and Choosing Urology

History of Prostate Surgery and Pat Walsh's Innovations

Prostatectomy Risks: Bleeding, Incontinence, and Sexual Function

Prostate Specific Antigen (PSA) Explained

PSA Screening Controversy and Impact on Metastatic Disease

Advanced Screening Tools: 4K Score, PHI, and MRI

Prostate Biopsy: Risks and Transperineal Approach

Gleason Grading System and Grade Groups

Testosterone, DHT, and Prostate Cancer Controversy

Prostate Metabolism and Exciting Research Areas

Benign Prostate Issues: Pelvic Pain and Infections

Advances in Surgical Technology: Robotic Prostatectomy

Male Contraceptive Options

Tyrosine Kinases

These are proteins that modify other proteins within a cell by adding a phosphate group to a tyrosine residue, transmitting acute signals. They act as 'rheostats' to fine-tune cellular signals rather than just turning them on or off, and are attractive targets for cancer drugs like Gleevec.

Prostate Specific Antigen (PSA)

PSA is a protein produced by prostate epithelial cells, primarily functioning to liquefy semen. While prostate-specific, it is not cancer-specific; its levels in the blood can indicate prostate size, inflammation, or the presence of cancer due to leakage from the prostate into the bloodstream.

PSA Density

This metric helps urologists fine-tune PSA interpretation by dividing the PSA value by the prostate gland's volume. A higher PSA density can raise a red flag for prostate cancer risk, even if the absolute PSA number appears 'normal' for the patient's age.

4K Score / Prostate Health Index (PHI)

These are advanced blood tests that measure multiple prostate-specific proteins (PSA, free PSA, intact PSA, HK2 for 4K; minus two pro PSA for PHI). They are designed to better discriminate between benign prostate conditions and high-grade, aggressive prostate cancer, providing a percentile chance of having aggressive cancer.

Gleason Grading System

Developed by pathologist Donald Gleason, this system grades prostate cancer based on the architectural appearance of glandular abnormalities under a microscope. It assigns a primary and secondary pattern (1-5), which are summed to a Gleason score (e.g., 3+3=6), and has evolved into a 5-tier Grade Group system for clearer communication of aggressiveness.

Active Surveillance

A management strategy for low-grade prostate cancer (typically Grade Group 1, Gleason 3+3) where the tumor is monitored over time with regular PSA tests, rectal exams, and sometimes repeat biopsies or MRIs, instead of immediate active treatment like surgery or radiation.

Non-Myelinated Nerves

Nerves, such as those responsible for erectile function around the prostate, that lack a myelin sheath. This makes them incredibly sensitive to any manipulation or trauma during surgery, contributing to the difficulty in preserving sexual function post-prostatectomy.

Androgen Output of Tumors

This refers to how much a prostate cancer tumor relies on or produces androgens (like testosterone) for its growth. Counterintuitively, the most aggressive prostate tumors often exhibit the lowest androgen output, while high-output tumors are typically more sensitive to androgen deprivation therapy.

?
What is the Prostate Specific Antigen (PSA) and what is its normal function?

PSA is a protein made by the prostate gland, and its normal function is to liquefy semen, which is important for sperm motility and egg fertilization.

?
What factors can cause PSA levels to rise in the blood?

PSA levels can rise due to aging (as the prostate enlarges and becomes 'leakier'), prostate infection (inflammation), or the presence of prostate cancer.

?
How does the 4K Score or Prostate Health Index (PHI) improve prostate cancer screening compared to PSA alone?

These tests measure multiple prostate-specific proteins to better differentiate between benign prostate conditions and high-grade, aggressive prostate cancer, providing a percentile chance of having aggressive cancer.

?
What is the Gleason grading system and how is it used to classify prostate cancer?

The Gleason system grades prostate cancer based on the architectural appearance of glandular abnormalities under a microscope, assigning a score (now a Grade Group 1-5) that indicates the tumor's aggressiveness.

?
What is the current understanding of testosterone replacement therapy (TRT) and its risk for prostate cancer?

Physiologic replacement of testosterone is not clearly linked to accelerating or causing prostate cancer to develop, and some data suggests the most aggressive tumors have low androgen output.

?
What are the primary risks associated with prostatectomy (surgical removal of the prostate)?

Historically, risks included extreme blood loss, urinary incontinence, and impotence. Modern techniques have significantly reduced these, but regaining full sexual function can still be challenging due to the sensitivity of non-myelinated nerves.

?
What is the current recommendation for prostate cancer screening?

Almost all guidelines now recommend a shared decision-making process between the physician and patient, considering individual risk factors and preferences, rather than a universal screening mandate.

?
What is the risk of infection or bleeding after a prostate biopsy?

While some minor bleeding is common, the risk of a significant infection requiring hospital admission is low, with one institution reporting 0.4% in their series, though national data might show higher ER visit rates.

?
What is the most exciting area of research in prostate cancer?

The most exciting research involves moving beyond prognostic biomarkers to predictive biomarkers, especially identifying DNA damage repair pathway mutations (like BRCA1/2) that predict sensitivity to specific drugs like PARP inhibitors.

?
What is chronic pelvic pain syndrome, and how is it related to prostatitis?

Chronic pelvic pain syndrome is a broader term encompassing burning or pain in the urethra and bladder, which can include non-bacterial prostatitis (inflammation of the prostate without a bacterial infection).

1. Shared Prostate Cancer Screening

Discuss prostate cancer screening with your physician as a shared decision-making process, as there is no universal formal recommendation and stopping aggressive screening has led to a rise in advanced disease.

2. Utilize 4K Score/PHI Test

Consider using the 4K score or Prostate Health Index (PHI) test to assess the percentile chance of having high-grade, aggressive prostate cancer, as these tests help discriminate between cancerous and benign cells.

3. High-Quality Prostate MRI

If undergoing a prostate MRI, ensure it is a multi-parametric MRI with high-quality diffusion-weighted imaging (DWI) performed and interpreted by skilled professionals, as DWI is the most important parameter.

4. Prostate Biopsy Decision Algorithm

Follow an algorithm where a biopsy is recommended for abnormal MRIs or negative MRIs with high PSA density (>0.15), but may not be needed for negative MRIs with low PSA density, which can reduce unnecessary biopsies.

5. Genetic Testing for Metastatic PCa

If diagnosed with metastatic prostate cancer, consider genetic testing for DNA damage repair pathway mutations (e.g., BRCA1/2, ATM), as these mutations are enriched and may indicate sensitivity to PARP inhibitors.

6. Physiologic Testosterone Replacement & PCa

Physiologic testosterone replacement therapy is not clearly shown to accelerate or cause prostate cancer development, and aggressive tumors often have low androgen output.

7. Manage Non-Bacterial Prostatitis

If experiencing non-bacterial prostatitis (chronic pelvic pain syndrome), focus on managing symptoms and adjusting risk factors like constipation, as antibiotics may not be necessary for inflammation without infection.

8. Prostatic Massage for Inflammation

For non-bacterial prostatitis, a prostatic massage may help alleviate symptoms by reducing inflammation, potentially providing relief without antibiotics.

9. Targeted Antibiotics for Recurrent Infection

If experiencing recurrent bacterial prostate infections, discuss direct antibiotic injections into the prostate or seminal vesicles with your urologist, as these areas can harbor persistent bacteria.

10. MD-PhD Clinical Experience

MD-PhD students should do clinical time before their PhD to gain a practical understanding of important clinical questions and the human condition, which can inform their research.

11. Continuous Professional Learning

Establish a regular ‘adult only’ journal club with colleagues (medonks, radonks, urologists) to review new research articles in your field and related specialties, fostering continuous learning and staying current.

12. Only Order Actionable Medical Tests

Do not order a medical test unless you know what you will do with the results and how they will alter your management plan for the patient.

13. Explore New Opportunities

Never walk by an open door without looking inside; view new opportunities as exploration rather than risk to foster personal and professional growth.

14. Vasectomy and Sperm Banking

If considering a vasectomy, consider sperm banking beforehand, and ensure a skilled professional performs the procedure, as reversal rates are high with good technique.

15. Practice Safe Sex

Use protection (e.g., condoms) for safe sex, not just for contraception, especially if dating, to prevent sexually transmitted infections.

16. Support The Drive Podcast

If you find value in The Drive podcast, consider becoming a member to support its production and gain access to exclusive content like show notes, transcripts, AMA episodes, and product deals.

You never walk by an open door without looking inside.

Ted Schaeffer

You can't make important discoveries unless you work on important problems.

Pat Walsh

Don't order a test, don't do a test unless you know what you're, what you're going to do.

Peter Attia

The most aggressive tumors are the ones that have low androgen output.

Ted Schaeffer

The pursuit of excellence is something I think about all the time. And that was really the epitome of Hopkins for me.

Ted Schaeffer

Prostate Cancer Screening and Biopsy Algorithm

Ted Schaeffer
  1. Perform a PHI (Prostate Health Index) or 4K score blood test as an initial assessment.
  2. If the PHI or 4K score is abnormal, proceed to a multi-parametric prostate MRI, specifically focusing on diffusion-weighted imaging (DWI).
  3. If the MRI shows a suspicious lesion, perform a biopsy that samples the suspicious lesion and includes systematic biopsies (e.g., right, left, top, middle, bottom).
  4. If the MRI is negative (no lesion) but the PSA density is high (e.g., more than 0.15), a biopsy is still recommended.
  5. If the MRI is negative and the PSA density is low, no biopsy is needed.
0.5 to 0.6 nanograms per ml
Normal median PSA for a 40-year-old man Age-adjusted, median for the population
1 nanogram per ml
Normal median PSA for a 50-year-old man Age-adjusted, median for the population
More than 2.5 nanograms per ml
PSA level considered abnormal for younger men May require further workup, not necessarily immediate biopsy
4 nanograms per ml
Historical arbitrary PSA cutoff for screening Originally set when PSA testing took off in the 1990s
50 times more potent
Dihydrotestosterone (DHT) potency relative to testosterone A very potent androgen in the body
40%
Incidence of metastatic prostate cancer at presentation (1990) Before widespread PSA screening
4%
Incidence of metastatic prostate cancer at presentation (2000) After widespread PSA screening implementation
0.4%
Prostate biopsy infection rate (Northwestern institution) Requiring hospital admission, based on institutional monitoring
~7%
Prostate biopsy ER/hospital visit rate (Medicare age population, national data) Within 30 days of a biopsy for any evaluation, potentially including non-infectious issues
20%
MRI false negative rate for prostate cancer Percentage of times an MRI may miss a lesion
40 grams
Median prostate volume for a 60-year-old man Used in PSA density calculations
More than 0.1 or 0.15
PSA density threshold for raising a red flag Depends on patient age and scenario, indicating higher likelihood of cancer
11-12%
Prevalence of DNA repair pathway mutations in germline of men with metastatic castrate-resistant prostate cancer Significantly enriched compared to the general population
Over one-third
Prevalence of DNA repair pathway mutations in tumors of men with metastatic castrate-resistant prostate cancer Making tumors sensitive to PARP inhibition